Warning: getimagesize(images/pics/538073-china-insulin-industry-report.jpg) [function.getimagesize]: failed to open stream: No such file or directory in /var/www/prinsidecom/htdocs/inc/release_details_print.php on line 69

China Insulin Industry Report, 2012-2015 published by ResearchInChina

2013-01-10 07:00:21 - ResearchInChina, the vertical portal for Chinese business intelligence, announces the release of a new report – China Insulin Industry Report, 2012-2015 . For more information, please contact us at or at 86-10-82600828.

For details of this report please visit

China is a country with the largest number of diabetics. In 2011, the market scale of diabetes medicine in China approximated RMB13.8 billion, of which, insulin medicines mainly comprising recombinant human insulin and insulin analog accounted for 52.8%.

Due to high technological content and entry barriers, Chinese insulin market is monopolized by foreign

corporations. In 2011, the combined market share of the three world-renowned pharmaceutical tycoons including Novo Nordisk, Eli Lilly and Company, and Sanofi Group hit 90% in the Chinese market. By contrast, the largest domestic counterpart- Tonghua Dongbao Pharmaceutical -occupied merely 3.4% or so.

Denmark-based Novo Nordisk is not only the leader in global insulin industry, but also a major supplier in China’s insulin market with the recombinant human insulin market share of 76% and the insulin analog market share of 53% in 2011.

America-based Eli Lilly and Company is the second embarking on Chinese insulin market, with the recombinant human insulin market share of 17% and the insulin analog market share of 8% in 2011. Moreover, Eli Lilly and Company is making constant efforts to extend business in the Chinese market. In May, 2012, Eli Lilly and Company China R&D center was formally opened in Shanghai, dedicated to the R&D of diabetes medicines; in June, the Suzhou-based insulin extension project with the investment exceeding USD40 million was also put into service.

Jilin-based Tonghua Dongbao Pharmaceutical is China’s largest recombinant human insulin producer, with the insulin API capacity of 3,000 kg and the insulin preparation capacity of 70 million bottles or 6% market share in China’s recombinant human insulin market. In 2012, the company’s recombinant human insulin injection phase Ⅲ project with the annual capacity of insulin preparation targeting 126 million pcs started construction, and it is expected to be put into production in Q4 2013.

As the world’s fourth and China’s first insulin analog producer, Gan & Lee Pharmaceuticals realized the market share of 6% in China’s insulin analog market in 2011. In April 2012, the insulin phase Ⅲ project of the company held the groundbreaking ceremony. Once the project is put into production as scheduled, the company is expected to increase its capacity of insulin API by 750kg/a and of insulin preparation by 38.5 mln pcs/a.

Enterprises including Hisun Pharmaceutical, United Laboratories and Bayer, with positive outlook of demand for insulin in the Chinese market, are beefing up gaining ground in China through developing new products, building new production bases and agent marketing.

The report highlights the followings:

Global insulin industry: development, supply & demand, product R&D, competition pattern, development trend, etc.
China insulin industry: development, supply & demand, import & export, competition pattern, policy environment, development trend, etc.
Operation, insulin business analysis and development outlook of seven insulin producers worldwide.

1. Insulin Overview
1.1 Definition
1.2 Classification
1.3 Industry Chain

2. Global Insulin Market Development
2.1 Status Quo
2.2 Supply and Demand
2.3 Product R&D
2.4 Competition Pattern
2.5 Development Trend

3. China Insulin Market Development
3.1 Status Quo
3.2 Supply and Demand
3.3 Export
3.4 Import
3.5 Competition Pattern
3.6 Price
3.7 Policy
3.8 Development Trend

4. Key Insulin Manufacturers
4.1 Novo Nordisk
4.1.1 Profile
4.1.2 Operation
4.1.3 Revenue Structure
4.1.4 Gross Margin
4.1.5 R&D and Investment
4.1.6 Insulin Business
4.1.7 Business in China
4.1.8 Development Prospect
4.2 Eli Lilly and Company
4.2.1 Profile
4.2.2 Operation
4.2.3 Revenue Structure
4.2.4 Gross Margin
4.2.5 R&D and Investment
4.2.6 Insulin Business
4.2.7 Business in China
4.2.8 Development Prospect
4.3 Sanofi Group
4.3.1 Profile
4.3.2 Operation
4.3.3 Revenue Structure
4.3.4 Gross Margin
4.3.5 R&D and Investment
4.3.6 Insulin Business
4.3.7 Business in China
4.3.8 Development Prospect
4.4 Tonghua Dongbao Pharmaceutical Co., Ltd.
4.4.1 Profile
4.4.2 Operation
4.4.3 Revenue Structure
4.4.4 Gross Margin
4.4.5 Customers
4.4.6 R & D and Investment
4.4.7 Insulin Business
4.4.8 Development Prospect
4.5 Wanbang Biopharmaceuticals
4.5.1 Profile
4.5.2 Operation
4.6 Gan & Lee Pharmaceuticals
4.6.1 Profile
4.6.2 Operation
4.7 Nanjing Xinbai Pharmaceutical Co. Ltd.
4.7.1 Profile
4.7.2 Operation
4.7.3 Insulin Business

Contact Information:

Haidian District, Beijing

Contact Person:
Liao Yan
Marketing Manager
Phone: 86-10-82600828
email: e-mail



liao yan

liao yan
Telefon: 86-10-82600828

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.